Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Lenvatinib in advanced melanoma (China Extension)
NCT04889118Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing Pembrolizumab+Lenvatinib with Pembrolizumab+Placebo (2 arms). Primary endpoints: Progression-Free Survival at 30 months and Overall Survival at 30 months. Started Jul 2020; status: completed.
02
Drugs
lenvatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04889118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889118.